Rimonabant in the management of cardiovascular risk
Future Prescriber · 2006
DOI: 10.1002/fps.13 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Prescriber, 2006. Verfasst von Anthony Barnett.
Abstract (Originalsprache)
The current obesity pandemic is recognised as a major factor contributing to the global burden of disease. Indeed, the rising tide of obesity in the USA and Europe has been shown to contribute directly to high levels of type 2 diabetes, cardiovascular disease and certain cancers. Increases in body weight leading to central obesity are associated with pathological changes in blood lipid profiles, predisposing subjects to atherosclerosis, and with metabolic changes in glycaemic control that contribute to cardiovascular damage. Copyright © 2006 John Wiley & Sons, Ltd.
Zitieren
APA
Barnett, A. (2006). Rimonabant in the management of cardiovascular risk. Future Prescriber. https://doi.org/10.1002/fps.13
Vancouver
Barnett A. Rimonabant in the management of cardiovascular risk. Future Prescriber. 2006. doi:10.1002/fps.13
BibTeX
@article{Barnett2006,
author = {Barnett, Anthony},
title = {Rimonabant in the management of cardiovascular risk},
journal = {Future Prescriber},
year = {2006},
doi = {10.1002/fps.13}
}
EUVIMED